Biography:
Devarshi Brahmbhatt, M.S, B.Pharm is a Principal Scientist at Calder Biosciences Inc. He graduated from Gujarat Technological University, with a Bachelor’s of Pharmacy degree and started working as a Pharmacist in India. He obtained a Master of Science in Pharmaceutical Sciences from Temple University, in Philadelphia and initially worked in a biologics manufacturing facility at Janssen Pharmaceuticals, Malvern, PA. With a deep passion for research, he joined Calder Biosciences Inc. in 2019. Calder Biosciences is a next generation vaccine research and development company using its proprietary “3D-Vaxlock” platform technology that provides conformational stability and generates immunogens that elicit more protective responses. Currently, he is working on RSV and Universal flu vaccine projects under the leadership of Drs. Christopher Marshall and Mark Yondola. He has accumulated extensive experience in vaccine research, development, and manufacturing.
Title : 3D- Vaxlock Technology stabilizes the prefusion conformation of the RSV F protein resulting in a highly potent and stable subunit vaccine candidate